NMI TT

home contact company.overview news sitemap print

Electrophysiology Services

Contact

NMI-TT Contact Person

Dr Udo Kraushaar

+49 7121 51530 851


Stem cell derived cardiomyocytes cluster on a MEA chip


9-well MEA chip for parallel drug testing


MEA-Cardiosensor

Do you need a relevant and robust cell model for drug safety testing?
Do you want a more clinically predictive cardiotoxicity assay?

Our Cardiosensor is a reliable and rapid system to test for drug effects on cardiac function, including QT-interval prolongation and arrhythmia in vitro


    Cell systems available:
  • Stem-cell derived cardiomyocytes
  • Primary cardiomyocytes from animal models

The assay is based on the extracellular recording of field action potentials (fAPs) of cardiomyocytes in culture with microelectrode arrays (MEAs). fAPs reflect the concerted activation and inactivation of cardiac ion channels, comparable to an electrocardiogram (ECG) in patients and are thus referred to here as “QT-interval” in vitro.

Drug-induced effects on cardiac function can be observed in our test system, as a prolongation of the fAP duration (“QT-interval in vitro”) and/or arrhythmic beating behaviour of the electrically coupled cardiomyocytes.

Download our latest presentation: Field action potential recordings of primary atrial and ventricular cardiomyocytes on microelectrode array

(MEA)


Cardiomyocytes after DIV 3 forming a syncytium of electrically coupled cells

Field action potentials (fAPs) recorded from cardiomyocytes at DIV3 representing the "QT interval


Effect of quinidine on "QT-interval" in vitro
Effect of quinidine on "QT-interval" in vitro


Dose-response curve for cisapride action on "QT-interval" in vitro
Dose-response curve for cisapride action on "QT-interval" in vitro


Drug-induced arrhythmia in cardiomyocytes (DIV 3 on MEA)
Drug-induced arrhythmia in cardiomyocytes (DIV 3 on MEA)
 
   

 

Linked in profile

NMI TT is a subsidiary of NMI